New possibilities for asthma therapy in children
https://doi.org/10.21518/2079-701X-2018-17-192-198
Abstract
This article discusses issues of clinical diagnosis and course of bronchial asthma in children. We discuss assessment of asthma severity and, accordingly, the extent of the step-by-step therapy according to updated recommendations (GINA 2018). Particular attention is paid to the possibility of improving the control of asthma with the help of the M-cholinolytic drug of long-acting tiotropium bromide, presented as a special inhalation form of tiotropium Respimat and registered in the Russian Federation for treatment of asthma in children of moderate and severe course from 6 years of age. Application tiotropium Respimat in children with insufficient control of asthma allows to improve lung function and asthma control.
About the Authors
T. N. Surovenko
Pacific state medical university
Russian Federation
Russian Federation
Е. F. Glushkova
NRC Institute of Immunology FMBA of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Pijnenburg M, Karin C. Lodrup Carlsen. Bronchial asthma. ERS Handbook: Paediatric Respiratory Medicine, 2013: 316-27.
2. Global Strategy for Asthma Management and Prevention. Revised 2018. www.ginasthma.com Ссылка активна на 06.09.2017.
3. The federal guidelines for the diagnosis and treatment of bronchial asthma. 2016. www.pulmonology.ru
4. Chuchalin AG, Khaltaev N, Antonov N. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federations. International Journal of COPD, 2014, 9: 963-974. doi: 10.2147/COPD.S67283.
5. National program “Bronchial asthma in children. The strategy for the prevention and treatment” 5th ed., revised and enlarged. M.: Original-maket, 2017. 160 p.
6. Kurbacheva OM, Galitskaya MA. The role of anti-leukotriene drugs in antiinflammatory therapy of bronchial asthma. Rossiyskiy Allergologicheskiy Zhurnal, 2017, (4-5): 71-78.
7. The Russian Federation Ministry of Health clinical guidelines “Bronchial Asthma in Children” (2017 revision) http://www.pediatr-russia.ru/sites/default/files/file/kr_bronhast.pdf the link is active on April 26, 2018.
8. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet, 2003 Mar 29, 361(9363): 1071-6.
9. Stempel DA, Raphiou IH, Kral KM, Yeakey AM, Emmett AH, Prazma CM et al. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. N Engl J Med, 2016 May 12, 374(19): 1822-30. doi: 10.1056/NEJMoa1511049. Epub 2016 Mar 6.
10. Haddad el-B, Rousell J. Regulation of the expression and function of the M2 muscarinic receptor. Trends Pharmacol Sci, 1998, 19(8): 322-327.
11. Joos GF. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch Chest Dis, 2000, 55(5): 411-414.
12. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, Hammer R. Ba 679 BR, a novel longacting anticholinergic bronchodilator. Life Sci, 1993, 52(5–6): 537–544.
13. Joos GF. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch Chest Dis, 2000, 55(5): 411–414.
14. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. References Pharmacol Ther, 2003, 98(1): 59-69.
15. Ayala LE, Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest, 1989, 96(6): 1285–1291.
16. Barnes PJ. Tiotropium bromide. Expert Opin Investig Drugs, 2001, 10(4): 733-40.
17. Ohta S, Oda N, Yokoe T, Tanaka A, Yamamoto Y, Watanabe Y. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy, 2010, 40(8): 1266–1275.
18. Buels KS, Jacoby DB, Fryer AD. Nonbronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br J Pharmacol, 2012, 165(5): 1501–1514.
19. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med, 2005, 18(3): 264-72.
20. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFAbeclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J, 1998, 12(6): 1346-53.
21. Knyazheskaya NP. The role of prolonged cholinolytics in bronchial asthma. Spravochnik Poliklinicheskogo Vracha, 2010, 11: 32-36.
22. Nenasheva NM. New opportunities to achieve control using tiotropium bromide. Effektivnaya Farmakoterapiya, 2014, 29: 4-13.
23. Nenasheva NM. Treatment of «difficult» bronchial asthma: new opportunities with tiotropium. Astma i Allergiya, 2015, 2: 27-31.
24. Geppe NA, Kolosova NG, Arkhipov VV, et al. The use of tiotropium as add-on treatment to the background therapy of bronchial asthma in children. Opinion of the Council of Experts of the Pediatric Respiratory Society. Voprosy Prakticheskoy Pediatrii, 2017, 12 (4): 77-84.
25. Hamelmann E et al. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial. J Allergy Clin Immunol, 2016, 138(2): 441-450.
26. Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J, 2017 Jan 11, 49(1).
27. Szefler SJ, Murphy K, Harper T 3rd, Boner A, Laki I, Engel M, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol, 2017 Feb 9. pii: S00916749(17)30218-X. doi: 10.1016/j.jaci.2017.01.014.
28. Vogelberg C, Laki I, Schmidt O, E Hamelmann. Safety and tolerability of oncedaily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma. European Respiratory Journal, 2016, 48: PA4399. (CanoTinA-астма®, NCT01634139).
29. Patient Information Leaflet for Spiriva® Respimat® Registration number: LP-000890.
Review
For citations:
Surovenko TN, Glushkova ЕF. New possibilities for asthma therapy in children. Meditsinskiy sovet = Medical Council. 2018;(17):192-199. (In Russ.) https://doi.org/10.21518/2079-701X-2018-17-192-198
Views:
1732
Email this article 